Table 2.
A: Immunohistochemical analysis of macrophage, osteoclast and T-lymphocyte markers; B. serum levels of the OS2006 patients (n = 108). Bonferroni’s adjustments were made to account for multiple testing.
| Included Patients | Total | ZA− | ZA+ | p adj |
|---|---|---|---|---|
| n = 108 | n = 69 | n = 39 | ||
| A.IHC | ||||
| CD8 (%) | ||||
| Med (Range) | 1 (0–60) | 1 (0–60) | 1 (0–30) | 1.0000 |
| Missing | 12 | 9 | 3 | |
| CD163 (%) | ||||
| Med (Range) | 40 (0–80) | 40 (0–80) | 40 (0–80) | 1.0000 |
| Missing | 27 | 18 | 9 | |
| CD68 (%) | ||||
| Med (Range) | 20 (0–80) | 20 (0–80) | 20 (0–80) | 1.0000 |
| Missing | 12 | 7 | 5 | |
| B.Serum levels | ||||
| At diagnosis | ||||
| CSF-1R (ng/mL) | ||||
| Med (Range) | 619.5 (159.0–1359.5) | 582.0 (159.0–1293.7) | 635.3 (175.7–1359.5) | 1.0000 |
| Missing | 4 | 2 | 2 | |
| TRAP (U/L) | ||||
| Med (Range) | 9.7 (2.2–48.5) | 9.2 (2.2–27.5) | 11.1 (2.2–48.5) | 1.0000 |
| Missing | 3 | 1 | 2 | |
| At surgery | ||||
| CSF-1R (ng/mL) | ||||
| Med (Range) | 683.1 (150.8–2262.1) | 619.2 (150.8–2034.8) | 854.1 (213.6–2262.1) | 1.0000 |
| Missing | 38 | 26 | 12 | |
| TRAP (U/L) | ||||
| Med (Range) | 6.9 (0.5–24.3) | 7.6 (3.5–24.3) | 5.1 (0.5–9.6) | 0.0011 |
| Missing | 41 | 27 | 14 | |
| At the end of treatment | ||||
| CSF-1R (ng/mL) | ||||
| Med (Range) | 716.9 (146.9–2714.5) | 676.3 (146.9–2714.5) | 831.8 (296.1–1988.1) | 1.0000 |
| Missing | 34 | 22 | 12 | |
| TRAP (U/L) | ||||
| Med (Range) | 6.5 (0.6–23.3) | 7.0 (2.1–23.3) | 3.7 (0.6–11.2) | 0.0132 |
| Missing | 36 | 24 | 12 | |
| One year after the end of treatment | ||||
| CSF-1R (ng/mL) | ||||
| Med (Range) | 518.7 (244.1–1788.4) | 499.6 (244.1–1788.4) | 615.9 (261.6–1452.4) | 1.0000 |
| Missing | 55 | 34 | 21 | |
| TRAP (U/L) | ||||
| Med (Range) | 6.2 (0.9–26.0) | 6.4 (2.2–26.0) | 5.5 (0.9–13.1) | 1.0000 |
| Missing | 57 | 34 | 23 |